Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031848 | 0.95 | MAP1LC3B (0.52) | MAP1LC3BSTAT3CRBNBRD4GSPT1 | |
| SCHEMBL25756460 | 0.95 | MAP1LC3B (0.52) | MAP1LC3BSTAT3CRBNBRD4GSPT1 | |
| SCHEMBL25756263 | 0.94 | MAP1LC3B (0.48) | MAP1LC3BSTAT3CRBNBRD4GSPT1 | |
| SCHEMBL25756266 | 0.91 | MAP1LC3B (0.49) | MAP1LC3BSTAT3CRBNBRD4GSPT1 | |
| SCHEMBL25756086 | 0.90 | MAP1LC3B (0.48) | MAP1LC3BSTAT3CRBNBRD4 | |
| SCHEMBL25032251 | 0.90 | STAT3 (0.52) | MAP1LC3BSTAT3CRBNBRD4IKZF3 | |
| SCHEMBL23772825 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNBRD4IKZF3 | |
| SCHEMBL23772670 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNBRD4IKZF3 | |
| SCHEMBL23772439 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNBRD4IKZF3 | |
| SCHEMBL25755864 | 0.88 | MAP1LC3B (0.46) | MAP1LC3BSTAT3CRBNBRD4GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134104-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2023-02-15 | — | — | EP | disclosed |